Years of research in the academic setting led scientific founders Shen Yu and Fred Ausubel to observe that resistant bacterial pathogens respond differently to antibiotics based on specific metabolic parameters. Most antibiotic screening methods use growth conditions optimized for rapid bacterial growth but poorly reflective of an actual infection setting. Through careful study of metabolic processes in bacteria, Octagon has developed a discovery platform that has identified novel antimicrobial targets in Gram negative pathogens. Some of these drug targets have analogous human orthologs. Octagon is further applying these insights to the development of novel medicines for autoimmune disorders such as psoriasis, lupus nephritis, and Sjogren’s syndrome.
This platform is being applied to additional promising compound libraries through collaboration with industry and academia. Contact us here to learn more about discovery partnership opportunities.